EpiPen Medicaid Rebates Could Increase As Mylan, CMS Dispute Heats Up
Executive Summary
Mylan, agency take opposing views on whether the company has been overcharging Medicaid for EpiPen, which is currently classified as a generic for the purposes of program rebates.
You may also be interested in...
Medicaid Discount Classification: Will Trump And Grassley Tag Team Against Pharma?
Confirmation hearing for HHS Nominee Price could give Sen. Grassley chance to get new administration on record prioritizing enforcement against drugs that have been providing smaller than appropriate Medicaid discounts.
Medicaid Rebates Will Get Broad OIG Review After EpiPen
HHS Inspector General tells congressional committee chairmen it will investigate whether other drugs may be improperly classified as generics in Medicaid to avoid higher rebate requirements.
Investors Relieved As Mylan Settlement Avoids Investigation
Mylan shares rallied on Oct. 7 following the company’s late-day Oct. 10 announcement that it agreed to settlement terms with the Department of Justice related to Epipen rebates for Medicaid prescriptions, but separate investigations and competition are looming.